PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
Phase 3
Terminated
- Conditions
- Pulmonary Arterial HypertensionPulmonary Hypertension
- Interventions
- Drug: SitaxsentanDrug: Placebo
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT00795639
- Locations
- 🇺🇦
Pfizer Investigational Site, Kyiv, Ukraine
Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 374
- Registration Number
- NCT00795509
A Study To Assess The Effect Of Linezolid On QTc Interval
Phase 1
Completed
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00795145
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00794365
Long Term Use of Somatropin in Patients Small for Gestational Age
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 920
- Registration Number
- NCT00793325
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00793546
- Locations
Pfizer Investigational Site
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: As per routinary clinical care
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 293
- Registration Number
- NCT00793403
- Locations
- 🇮🇹
Pfizer Investigational Site, Torino, Italy
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: As per clinical practice
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 299
- Registration Number
- NCT00794118
- Locations
- 🇮🇹
Pfizer Investigational Site, Roma, Italy
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Phase 4
Completed
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00793871
- Locations
- 🇨🇳
Nanjing Bayi Hospital, Nanjing, Jiangsu, China
🇨🇳Cancer Institute & Hospital Chinese Academy of Medical Sciences and PUMC, Bejing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Tract Infections
- Interventions
- Drug: PF-04287881Drug: Placebo
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT00793000
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath